Legend Biotech Corp.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Latest on Legend Biotech Corp.
By following AstraZeneca in acquiring its own in vivo CAR-T company, AbbVie can now hedge its bets with investments across two distinct delivery platforms for the novel products. AbbVie’s decision t
The US Food and Drug Administration’s decision to remove Risk Evaluation and Mitigation Strategies (REMS) requirements for CAR-T cell therapies and streamline patient monitoring will likely expand the
Johnson & Johnson has sought to carve out a leading position in the treatment of multiple myeloma, and presentations at the American Society of Clinical Oncology and European Hematology Associatio
Bristol Myers Squibb’s CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) may see an expansion in its addressable population with positive Phase II data in marginal zone lymphoma (MZL). The drugma